Geneos Wealth Management Inc. Boosts Stake in Axon Enterprise, Inc $AXON

by · The Cerbat Gem

Geneos Wealth Management Inc. lifted its holdings in Axon Enterprise, Inc (NASDAQ:AXON – Free Report) by 11.8% during the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 2,065 shares of the biotechnology company’s stock after purchasing an additional 218 shares during the period. Geneos Wealth Management Inc.’s holdings in Axon Enterprise were worth $1,086,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of AXON. Brighton Jones LLC purchased a new position in shares of Axon Enterprise in the fourth quarter worth about $480,000. OMERS ADMINISTRATION Corp lifted its stake in shares of Axon Enterprise by 20.5% in the fourth quarter. OMERS ADMINISTRATION Corp now owns 2,987 shares of the biotechnology company’s stock worth $1,775,000 after buying an additional 509 shares in the last quarter. NorthRock Partners LLC purchased a new position in shares of Axon Enterprise in the fourth quarter worth about $555,000. Mufg Securities Americas Inc. acquired a new stake in Axon Enterprise during the fourth quarter worth about $636,000. Finally, Quantinno Capital Management LP increased its position in Axon Enterprise by 11.2% during the fourth quarter. Quantinno Capital Management LP now owns 8,724 shares of the biotechnology company’s stock worth $5,185,000 after purchasing an additional 878 shares during the last quarter. 79.08% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Axon Enterprise

In other Axon Enterprise news, CEO Patrick W. Smith sold 10,000 shares of Axon Enterprise stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $743.64, for a total transaction of $7,436,400.00. Following the completion of the sale, the chief executive officer directly owned 3,043,982 shares in the company, valued at $2,263,626,774.48. This trade represents a 0.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Hadi Partovi purchased 1,358 shares of the company’s stock in a transaction on Wednesday, August 13th. The shares were bought at an average price of $740.00 per share, with a total value of $1,004,920.00. Following the completion of the transaction, the director owned 237,938 shares of the company’s stock, valued at approximately $176,074,120. The trade was a 0.57% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 44,790 shares of company stock valued at $34,304,947. 4.40% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on AXON shares. Morgan Stanley set a $885.00 price objective on shares of Axon Enterprise and gave the stock an “overweight” rating in a research report on Friday, July 11th. Wolfe Research started coverage on shares of Axon Enterprise in a research report on Monday, July 7th. They set an “outperform” rating for the company. JPMorgan Chase & Co. raised their price objective on shares of Axon Enterprise from $730.00 to $850.00 and gave the stock an “overweight” rating in a research report on Thursday, July 17th. Northland Securities set a $800.00 price objective on shares of Axon Enterprise in a research report on Tuesday, August 5th. Finally, UBS Group restated a “neutral” rating and set a $840.00 price objective (up from $820.00) on shares of Axon Enterprise in a research report on Tuesday, August 5th. Thirteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $837.69.

View Our Latest Stock Report on AXON

Axon Enterprise Price Performance

Shares of AXON opened at $756.13 on Friday. Axon Enterprise, Inc has a 1-year low of $375.71 and a 1-year high of $885.91. The stock has a market cap of $59.36 billion, a PE ratio of 186.70, a P/E/G ratio of 27.57 and a beta of 1.40. The firm has a 50-day simple moving average of $761.10 and a two-hundred day simple moving average of $686.46. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.95 and a quick ratio of 2.71.

Axon Enterprise (NASDAQ:AXON – Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The biotechnology company reported $2.12 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.58. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The business had revenue of $668.54 million during the quarter, compared to analysts’ expectations of $641.77 million. During the same period last year, the business earned $1.20 earnings per share. The business’s revenue for the quarter was up 32.6% on a year-over-year basis. Axon Enterprise has set its FY 2025 guidance at EPS. As a group, analysts forecast that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Axon Enterprise Company Profile

(Free Report)

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

See Also

Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc (NASDAQ:AXON – Free Report).